Clovis Oncology , Nasdaq: CLVS
Biotech formed by Pharmion execs to develop pancreas and lung cancer drugs.
Industry: Health Care
First Day Return: -3.4%
CLVS
Biotech formed by Pharmion execs to develop pancreas and lung cancer drugs.
| IPO Data | |
|---|---|
| IPO Date | 11/15/2011 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $130 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Boulder, CO, United States |
| Founded | 2009 |
| Employees at IPO | 45 |
| Website www.clovisoncology.com | |
IPO News for Clovis Oncology
Clovis Oncology (CLVS) Performance
